More manufacturing problems at Genzyme will affect supplies of Thyrogen used in the treatment of thyroid cancer. Due to the problems, the company has informed the EU that it will only be able to meet 45 percent of demand there until mid-July.
Genzyme also expects shortages in the US from mid-April through to mid-July. Regional disparities in supply are expected to continue because of logistical challenges related to the limited inventory. Genzyme is petitioning the regulatory agency to allow it to shift fill/finish operations to help alleviate the problem.
Posted by Bruce Lehr March 21st 2011.